StockNews.com downgraded shares of Corcept Therapeutics (NASDAQ:CORT – Get Rating) from a strong-buy rating to a buy rating in a research report report published on Monday morning.
Separately, HC Wainwright reduced their price objective on shares of Corcept Therapeutics from $33.00 to $30.00 and set a buy rating for the company in a research report on Friday, December 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $31.25.
Get Corcept Therapeutics alerts:Corcept Therapeutics Trading Down 1.2 %
Shares of NASDAQ:CORT opened at $22.99 on Monday. The company has a 50 day moving average of $22.31 and a 200-day moving average of $25.28. Corcept Therapeutics has a twelve month low of $17.19 and a twelve month high of $30.14. The firm has a market cap of $2.47 billion, a P/E ratio of 22.99 and a beta of 0.59.
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last posted its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.07. Corcept Therapeutics had a net margin of 29.37% and a return on equity of 27.49%. The business had revenue of $101.73 million during the quarter, compared to the consensus estimate of $107.73 million. Equities research analysts forecast that Corcept Therapeutics will post 0.89 EPS for the current year.Insider Transactions at Corcept Therapeutics
In other news, insider Gary Charles Robb sold 4,814 shares of the company's stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $26.03, for a total value of $125,308.42. Following the completion of the transaction, the insider now owns 21,329 shares of the company's stock, valued at $555,193.87. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Corcept Therapeutics news, insider Gary Charles Robb sold 4,814 shares of the company's stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $26.03, for a total transaction of $125,308.42. Following the sale, the insider now directly owns 21,329 shares in the company, valued at $555,193.87. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Sean Maduck sold 25,000 shares of the firm's stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $25.57, for a total value of $639,250.00. Following the transaction, the insider now owns 56,462 shares in the company, valued at $1,443,733.34. The disclosure for this sale can be found here. Insiders sold 40,439 shares of company stock worth $1,040,958 over the last quarter. 18.60% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Corcept Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Gladius Capital Management LP purchased a new position in shares of Corcept Therapeutics in the 2nd quarter valued at about $31,000. Quadrant Capital Group LLC boosted its holdings in Corcept Therapeutics by 714.0% in the 3rd quarter. Quadrant Capital Group LLC now owns 1,571 shares of the biotechnology company's stock worth $40,000 after buying an additional 1,378 shares during the last quarter. Altshuler Shaham Ltd boosted its holdings in Corcept Therapeutics by 67.6% in the 3rd quarter. Altshuler Shaham Ltd now owns 2,286 shares of the biotechnology company's stock worth $58,000 after buying an additional 922 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Corcept Therapeutics by 2,286.8% in the 2nd quarter. Lazard Asset Management LLC now owns 2,530 shares of the biotechnology company's stock worth $60,000 after buying an additional 2,424 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Corcept Therapeutics in the 2nd quarter worth about $76,000. Hedge funds and other institutional investors own 80.08% of the company's stock.
Corcept Therapeutics Company Profile
(Get Rating)
Corcept Therapeutics, Inc is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol.
Recommended Stories
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
- SoFi Technologies Smashes Earnings but Beware the Fed Decision
- Buying The Dip In Colgate-Palmolive
- Mullen Automotive On Hiring Spree, What Could That Mean?
- InterDigital Raises Its Earnings Guidance
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.